ArticlePediatric research2025
Identification of childhood-onset lupus nephritis through integrative bioinformatics: otoferlin as a novel biomarker.
Article in Pediatric research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial intelligence in pediatric nephrology: current applications and emerging frameworks for evidence generation.Pediatric nephrology (Berlin, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChildhood-onset systemic lupus erythematosus (cSLE) exhibits a higher incidence of lupus nephritis (LN) compared to adult-onset SLE (aSLE). However, the underlying molecular mechanisms remain elusive.
methodsGene expression datasets from childhood-onset (GSE65391) and adult-onset (GSE72798) LN patients were obtained. Differential gene expression (DEG) and weighted gene co-expression network analysis (WGCNA) identified key modules associated with cLN. Machine learning algorithms (random forest, SVM-RFE) prioritized hub genes, validated by ROC curves. Immune cell profiles analysis (CIBERSORT, ssGSEA, xCell) evaluated immune cell profiles, and functional enrichment (GSEA, GSVA) explored pathway alterations. Molecular docking and drug sensitivity analysis predicted therapeutic targets for otoferlin (OTOF)-high cLN.
resultsDistinct gene expression profiles were revealed between cLN and aLN, with significant enrichment of interferon (IFN) pathways in cLN. OTOF emerged as a high diagnostic biomarker for cLN, and was positively correlated with activated dendritic cells and associated with the TLR signaling pathway in cLN. Molecular docking predicted strong binding of OTOF to JAK inhibitors, supported by CMap analysis showing sensitivity of OTOF-high cLN to these drugs.
conclusionsIFN-related pathways are crucial for the pathogenesis of cLN. OTOF is a promising blood biomarker and contributes to cLN progression through IFN-related pathways. IMPACT: The molecular mechanisms by which cSLE is more likely to progress to cLN than aSLE are rarely investigated. The crucial role of interferon pathways in cLN pathogenesis is highlighted. OTOF could serve as an early diagnostic biomarker for cLN and promote cLN progression through TLRs. These insights could guide tailored therapeutic strategies for cLN, addressing a critical gap in current clinical management.
Indexed as
Identifiers
40789933What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.